nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—SELE—vein—rectum cancer	0.098	0.104	CbGeAlD
Carvedilol—VCAM1—vein—rectum cancer	0.0902	0.0955	CbGeAlD
Carvedilol—NPPB—smooth muscle tissue—rectum cancer	0.0216	0.0229	CbGeAlD
Carvedilol—SELE—seminal vesicle—rectum cancer	0.0174	0.0185	CbGeAlD
Carvedilol—VCAM1—seminal vesicle—rectum cancer	0.016	0.017	CbGeAlD
Carvedilol—HIF1A—seminal vesicle—rectum cancer	0.0154	0.0163	CbGeAlD
Carvedilol—SELE—epithelium—rectum cancer	0.0151	0.016	CbGeAlD
Carvedilol—GJA1—seminal vesicle—rectum cancer	0.015	0.0158	CbGeAlD
Carvedilol—SELE—smooth muscle tissue—rectum cancer	0.0146	0.0154	CbGeAlD
Carvedilol—SELE—renal system—rectum cancer	0.014	0.0149	CbGeAlD
Carvedilol—VCAM1—epithelium—rectum cancer	0.0139	0.0147	CbGeAlD
Carvedilol—SELE—urethra—rectum cancer	0.0138	0.0146	CbGeAlD
Carvedilol—VCAM1—smooth muscle tissue—rectum cancer	0.0134	0.0142	CbGeAlD
Carvedilol—HIF1A—epithelium—rectum cancer	0.0134	0.0142	CbGeAlD
Carvedilol—SELE—mammalian vulva—rectum cancer	0.0131	0.0139	CbGeAlD
Carvedilol—NDUFC2—seminal vesicle—rectum cancer	0.013	0.0138	CbGeAlD
Carvedilol—GJA1—epithelium—rectum cancer	0.013	0.0138	CbGeAlD
Carvedilol—VCAM1—renal system—rectum cancer	0.0129	0.0137	CbGeAlD
Carvedilol—HIF1A—smooth muscle tissue—rectum cancer	0.0129	0.0137	CbGeAlD
Carvedilol—VCAM1—urethra—rectum cancer	0.0127	0.0134	CbGeAlD
Carvedilol—GJA1—smooth muscle tissue—rectum cancer	0.0125	0.0133	CbGeAlD
Carvedilol—HIF1A—renal system—rectum cancer	0.0124	0.0132	CbGeAlD
Carvedilol—HIF1A—urethra—rectum cancer	0.0122	0.0129	CbGeAlD
Carvedilol—VCAM1—mammalian vulva—rectum cancer	0.0121	0.0128	CbGeAlD
Carvedilol—GJA1—renal system—rectum cancer	0.0121	0.0128	CbGeAlD
Carvedilol—GJA1—urethra—rectum cancer	0.0118	0.0125	CbGeAlD
Carvedilol—HIF1A—mammalian vulva—rectum cancer	0.0116	0.0123	CbGeAlD
Carvedilol—NDUFC2—epithelium—rectum cancer	0.0113	0.012	CbGeAlD
Carvedilol—GJA1—mammalian vulva—rectum cancer	0.0113	0.0119	CbGeAlD
Carvedilol—SELE—female reproductive system—rectum cancer	0.0112	0.0119	CbGeAlD
Carvedilol—NDUFC2—renal system—rectum cancer	0.0105	0.0111	CbGeAlD
Carvedilol—VCAM1—female reproductive system—rectum cancer	0.0103	0.011	CbGeAlD
Carvedilol—NDUFC2—urethra—rectum cancer	0.0103	0.0109	CbGeAlD
Carvedilol—SELE—vagina—rectum cancer	0.0102	0.0108	CbGeAlD
Carvedilol—HIF1A—female reproductive system—rectum cancer	0.00996	0.0105	CbGeAlD
Carvedilol—VEGFA—smooth muscle tissue—rectum cancer	0.00989	0.0105	CbGeAlD
Carvedilol—NDUFC2—mammalian vulva—rectum cancer	0.00982	0.0104	CbGeAlD
Carvedilol—GJA1—female reproductive system—rectum cancer	0.00966	0.0102	CbGeAlD
Carvedilol—VCAM1—vagina—rectum cancer	0.00936	0.00991	CbGeAlD
Carvedilol—VEGFA—urethra—rectum cancer	0.00935	0.0099	CbGeAlD
Carvedilol—HIF1A—vagina—rectum cancer	0.009	0.00953	CbGeAlD
Carvedilol—VEGFA—mammalian vulva—rectum cancer	0.00891	0.00943	CbGeAlD
Carvedilol—ADRB3—female reproductive system—rectum cancer	0.00885	0.00937	CbGeAlD
Carvedilol—GJA1—vagina—rectum cancer	0.00873	0.00925	CbGeAlD
Carvedilol—XDH—renal system—rectum cancer	0.00848	0.00897	CbGeAlD
Carvedilol—NDUFC2—female reproductive system—rectum cancer	0.00841	0.0089	CbGeAlD
Carvedilol—XDH—mammalian vulva—rectum cancer	0.00793	0.00839	CbGeAlD
Carvedilol—NDUFC2—vagina—rectum cancer	0.0076	0.00805	CbGeAlD
Carvedilol—VEGFA—vagina—rectum cancer	0.0069	0.0073	CbGeAlD
Carvedilol—XDH—female reproductive system—rectum cancer	0.00679	0.00719	CbGeAlD
Carvedilol—ADRA1D—epithelium—rectum cancer	0.00671	0.0071	CbGeAlD
Carvedilol—SELE—lymph node—rectum cancer	0.00658	0.00697	CbGeAlD
Carvedilol—ADRA1B—renal system—rectum cancer	0.00636	0.00673	CbGeAlD
Carvedilol—XDH—vagina—rectum cancer	0.00614	0.0065	CbGeAlD
Carvedilol—ADRA1D—urethra—rectum cancer	0.00611	0.00647	CbGeAlD
Carvedilol—VCAM1—lymph node—rectum cancer	0.00605	0.00641	CbGeAlD
Carvedilol—HIF1A—lymph node—rectum cancer	0.00582	0.00616	CbGeAlD
Carvedilol—GJA1—lymph node—rectum cancer	0.00565	0.00598	CbGeAlD
Carvedilol—ADRA1D—female reproductive system—rectum cancer	0.00498	0.00527	CbGeAlD
Carvedilol—NDUFC2—lymph node—rectum cancer	0.00492	0.00521	CbGeAlD
Carvedilol—VEGFA—lymph node—rectum cancer	0.00446	0.00472	CbGeAlD
Carvedilol—KCNH2—seminal vesicle—rectum cancer	0.00428	0.00453	CbGeAlD
Carvedilol—ADRA2C—seminal vesicle—rectum cancer	0.00423	0.00447	CbGeAlD
Carvedilol—ADRA1A—epithelium—rectum cancer	0.00385	0.00408	CbGeAlD
Carvedilol—VCAM1—Beta1 integrin cell surface interactions—ITGA2—rectum cancer	0.00382	0.0691	CbGpPWpGaD
Carvedilol—VCAM1—Integrin cell surface interactions—ITGA2—rectum cancer	0.00382	0.0691	CbGpPWpGaD
Carvedilol—ADRB1—female reproductive system—rectum cancer	0.00362	0.00383	CbGeAlD
Carvedilol—ADRA1A—renal system—rectum cancer	0.00357	0.00378	CbGeAlD
Carvedilol—KCNH2—renal system—rectum cancer	0.00345	0.00365	CbGeAlD
Carvedilol—ADRA2C—renal system—rectum cancer	0.0034	0.0036	CbGeAlD
Carvedilol—KCNH2—urethra—rectum cancer	0.00339	0.00359	CbGeAlD
Carvedilol—ADRA2A—seminal vesicle—rectum cancer	0.00337	0.00357	CbGeAlD
Carvedilol—ADRA2C—urethra—rectum cancer	0.00334	0.00354	CbGeAlD
Carvedilol—CYP2E1—seminal vesicle—rectum cancer	0.0033	0.00349	CbGeAlD
Carvedilol—VEGFA—Plexin-D1 Signaling—ITGA2—rectum cancer	0.00328	0.0594	CbGpPWpGaD
Carvedilol—GJA1—Arrhythmogenic Right Ventricular Cardiomyopathy—ITGA2—rectum cancer	0.0032	0.058	CbGpPWpGaD
Carvedilol—ADRA2C—mammalian vulva—rectum cancer	0.00318	0.00337	CbGeAlD
Carvedilol—PTGS1—seminal vesicle—rectum cancer	0.00318	0.00336	CbGeAlD
Carvedilol—CYP1A1—epithelium—rectum cancer	0.00314	0.00333	CbGeAlD
Carvedilol—CYP1A2—renal system—rectum cancer	0.00295	0.00313	CbGeAlD
Carvedilol—CYP1A1—renal system—rectum cancer	0.00291	0.00308	CbGeAlD
Carvedilol—CYP1A1—urethra—rectum cancer	0.00286	0.00303	CbGeAlD
Carvedilol—KCNH2—female reproductive system—rectum cancer	0.00276	0.00293	CbGeAlD
Carvedilol—PTGS1—epithelium—rectum cancer	0.00276	0.00292	CbGeAlD
Carvedilol—CYP1A1—mammalian vulva—rectum cancer	0.00273	0.00288	CbGeAlD
Carvedilol—ADRA2A—urethra—rectum cancer	0.00267	0.00282	CbGeAlD
Carvedilol—PTGS1—smooth muscle tissue—rectum cancer	0.00266	0.00282	CbGeAlD
Carvedilol—CYP2E1—renal system—rectum cancer	0.00266	0.00281	CbGeAlD
Carvedilol—CYP2E1—urethra—rectum cancer	0.00261	0.00276	CbGeAlD
Carvedilol—PTGS1—renal system—rectum cancer	0.00256	0.00271	CbGeAlD
Carvedilol—ADRA2A—mammalian vulva—rectum cancer	0.00254	0.00269	CbGeAlD
Carvedilol—KCNH2—vagina—rectum cancer	0.0025	0.00265	CbGeAlD
Carvedilol—ADRA2C—vagina—rectum cancer	0.00247	0.00261	CbGeAlD
Carvedilol—PTGS1—mammalian vulva—rectum cancer	0.00239	0.00253	CbGeAlD
Carvedilol—CYP1A1—female reproductive system—rectum cancer	0.00233	0.00247	CbGeAlD
Carvedilol—CYP2C9—female reproductive system—rectum cancer	0.00225	0.00238	CbGeAlD
Carvedilol—ADRA2A—female reproductive system—rectum cancer	0.00218	0.0023	CbGeAlD
Carvedilol—CYP3A4—renal system—rectum cancer	0.00214	0.00226	CbGeAlD
Carvedilol—CYP2E1—female reproductive system—rectum cancer	0.00213	0.00225	CbGeAlD
Carvedilol—CYP1A1—vagina—rectum cancer	0.00211	0.00223	CbGeAlD
Carvedilol—CYP2D6—renal system—rectum cancer	0.0021	0.00223	CbGeAlD
Carvedilol—PTGS1—female reproductive system—rectum cancer	0.00205	0.00217	CbGeAlD
Carvedilol—HIF1A—Hypoxic and oxygen homeostasis regulation of HIF-1-alpha—TP53—rectum cancer	0.00197	0.0357	CbGpPWpGaD
Carvedilol—ADRA2A—vagina—rectum cancer	0.00197	0.00208	CbGeAlD
Carvedilol—ABCB1—seminal vesicle—rectum cancer	0.00188	0.00199	CbGeAlD
Carvedilol—PTGS1—vagina—rectum cancer	0.00185	0.00196	CbGeAlD
Carvedilol—CYP3A4—female reproductive system—rectum cancer	0.00171	0.00181	CbGeAlD
Carvedilol—CYP2D6—female reproductive system—rectum cancer	0.00169	0.00178	CbGeAlD
Carvedilol—ABCB1—epithelium—rectum cancer	0.00163	0.00173	CbGeAlD
Carvedilol—KCNH2—lymph node—rectum cancer	0.00162	0.00171	CbGeAlD
Carvedilol—ADRA2C—lymph node—rectum cancer	0.0016	0.00169	CbGeAlD
Carvedilol—ABCB1—renal system—rectum cancer	0.00151	0.0016	CbGeAlD
Carvedilol—ABCB1—urethra—rectum cancer	0.00149	0.00157	CbGeAlD
Carvedilol—VEGFA—Beta1 integrin cell surface interactions—ITGA2—rectum cancer	0.00146	0.0264	CbGpPWpGaD
Carvedilol—ABCB1—mammalian vulva—rectum cancer	0.00142	0.0015	CbGeAlD
Carvedilol—CYP1A1—lymph node—rectum cancer	0.00137	0.00145	CbGeAlD
Carvedilol—ADRA2A—lymph node—rectum cancer	0.00127	0.00135	CbGeAlD
Carvedilol—VCAM1—Extracellular matrix organization—ITGA2—rectum cancer	0.00126	0.0228	CbGpPWpGaD
Carvedilol—SELE—TNF alpha Signaling Pathway—NRAS—rectum cancer	0.00125	0.0226	CbGpPWpGaD
Carvedilol—ABCB1—female reproductive system—rectum cancer	0.00121	0.00128	CbGeAlD
Carvedilol—PTGS1—lymph node—rectum cancer	0.0012	0.00127	CbGeAlD
Carvedilol—SELE—Cell surface interactions at the vascular wall—NRAS—rectum cancer	0.00118	0.0213	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—ITGA2—rectum cancer	0.00114	0.0206	CbGpPWpGaD
Carvedilol—ADRB2—Arf6 trafficking events—ITGA2—rectum cancer	0.00112	0.0202	CbGpPWpGaD
Carvedilol—ABCB1—vagina—rectum cancer	0.0011	0.00116	CbGeAlD
Carvedilol—SELE—TNF alpha Signaling Pathway—KRAS—rectum cancer	0.00107	0.0194	CbGpPWpGaD
Carvedilol—SELE—Glucocorticoid receptor regulatory network—TP53—rectum cancer	0.00105	0.0189	CbGpPWpGaD
Carvedilol—SELE—Cell surface interactions at the vascular wall—KRAS—rectum cancer	0.00101	0.0183	CbGpPWpGaD
Carvedilol—XDH—Nucleotide metabolism—TYMS—rectum cancer	0.000972	0.0176	CbGpPWpGaD
Carvedilol—SELE—TNF alpha Signaling Pathway—HRAS—rectum cancer	0.000913	0.0165	CbGpPWpGaD
Carvedilol—SELE—Cell surface interactions at the vascular wall—HRAS—rectum cancer	0.000861	0.0156	CbGpPWpGaD
Carvedilol—HIF1A—Oncostatin M Signaling Pathway—KRAS—rectum cancer	0.000829	0.015	CbGpPWpGaD
Carvedilol—HIF1A—Oncostatin M Signaling Pathway—TP53—rectum cancer	0.000737	0.0133	CbGpPWpGaD
Carvedilol—GJA1—AP-1 transcription factor network—TP53—rectum cancer	0.00072	0.013	CbGpPWpGaD
Carvedilol—ABCB1—lymph node—rectum cancer	0.000709	0.000751	CbGeAlD
Carvedilol—HIF1A—Oncostatin M Signaling Pathway—HRAS—rectum cancer	0.000705	0.0127	CbGpPWpGaD
Carvedilol—VEGFA—VEGFR2 mediated cell proliferation—NRAS—rectum cancer	0.000698	0.0126	CbGpPWpGaD
Carvedilol—HIF1A—AP-1 transcription factor network—TP53—rectum cancer	0.000694	0.0126	CbGpPWpGaD
Carvedilol—VEGFA—Focal Adhesion—ITGA2—rectum cancer	0.000627	0.0113	CbGpPWpGaD
Carvedilol—VEGFA—VEGFR2 mediated cell proliferation—KRAS—rectum cancer	0.000601	0.0109	CbGpPWpGaD
Carvedilol—VEGFA—Bladder Cancer—TP53—rectum cancer	0.000575	0.0104	CbGpPWpGaD
Carvedilol—VEGFA—Bladder Cancer—HRAS—rectum cancer	0.00055	0.00995	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000548	0.00992	CbGpPWpGaD
Carvedilol—VEGFA—VEGFR2 mediated cell proliferation—HRAS—rectum cancer	0.000511	0.00924	CbGpPWpGaD
Carvedilol—HIF1A—Signaling by NOTCH—TP53—rectum cancer	0.000487	0.00882	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—TP53—rectum cancer	0.000474	0.00858	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000472	0.00854	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—NRAS—rectum cancer	0.000455	0.00824	CbGpPWpGaD
Carvedilol—GJA1—EGF/EGFR Signaling Pathway—KRAS—rectum cancer	0.000414	0.00749	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—ITGA2—rectum cancer	0.000409	0.0074	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.000405	0.00732	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000401	0.00726	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—KRAS—rectum cancer	0.000392	0.00709	CbGpPWpGaD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—KRAS—rectum cancer	0.000358	0.00647	CbGpPWpGaD
Carvedilol—GJA1—EGF/EGFR Signaling Pathway—HRAS—rectum cancer	0.000352	0.00637	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000338	0.00611	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—HRAS—rectum cancer	0.000333	0.00603	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—NRAS—rectum cancer	0.000319	0.00578	CbGpPWpGaD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—TP53—rectum cancer	0.000318	0.00575	CbGpPWpGaD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—HRAS—rectum cancer	0.000304	0.0055	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—ITGA2—rectum cancer	0.000292	0.00528	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000291	0.00526	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—ITGA2—rectum cancer	0.000286	0.00518	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—rectum cancer	0.000279	0.00505	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—KRAS—rectum cancer	0.000275	0.00497	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—NRAS—rectum cancer	0.000263	0.00476	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000247	0.00447	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—TP53—rectum cancer	0.000244	0.00442	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—rectum cancer	0.00024	0.00434	CbGpPWpGaD
Carvedilol—HIF1A—Cellular responses to stress—TP53—rectum cancer	0.00024	0.00434	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—HRAS—rectum cancer	0.000234	0.00423	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—KRAS—rectum cancer	0.000227	0.0041	CbGpPWpGaD
Carvedilol—VEGFA—EPH-Ephrin signaling—HRAS—rectum cancer	0.000226	0.0041	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—TYMS—rectum cancer	0.000226	0.00409	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000212	0.00384	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—rectum cancer	0.000204	0.00369	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—HRAS—rectum cancer	0.000193	0.00349	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000183	0.0033	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—KRAS—rectum cancer	0.000182	0.0033	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—NRAS—rectum cancer	0.000182	0.00329	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—SLC14A2—rectum cancer	0.000181	0.00328	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—ITGA2—rectum cancer	0.000169	0.00305	CbGpPWpGaD
Carvedilol—ADRA1B—LPA receptor mediated events—HRAS—rectum cancer	0.000167	0.00302	CbGpPWpGaD
Carvedilol—ADRA1B—AMPK Signaling—TP53—rectum cancer	0.000164	0.00297	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—TP53—rectum cancer	0.000162	0.00293	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—ITGA2—rectum cancer	0.000158	0.00285	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—KRAS—rectum cancer	0.000157	0.00283	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	0.000155	0.00281	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000151	0.00273	CbGpPWpGaD
Carvedilol—ADRA1A—AMPK Signaling—TP53—rectum cancer	0.000146	0.00264	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—rectum cancer	0.000135	0.00245	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000134	0.00243	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HRAS—rectum cancer	0.000133	0.00241	CbGpPWpGaD
Carvedilol—VEGFA—Focal Adhesion—HRAS—rectum cancer	0.000129	0.00233	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—ITGA2—rectum cancer	0.000128	0.00232	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.000125	0.00226	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—rectum cancer	0.000116	0.00211	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—NRAS—rectum cancer	0.000115	0.00208	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—NRAS—rectum cancer	0.00011	0.002	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—rectum cancer	0.000104	0.00189	CbGpPWpGaD
Carvedilol—VEGFA—Cellular responses to stress—TP53—rectum cancer	0.000104	0.00187	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—rectum cancer	9.9e-05	0.00179	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—KRAS—rectum cancer	9.9e-05	0.00179	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—KRAS—rectum cancer	9.5e-05	0.00172	CbGpPWpGaD
Carvedilol—HIF1A—Disease—NRAS—rectum cancer	9.03e-05	0.00163	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	8.97e-05	0.00162	CbGpPWpGaD
Carvedilol—XDH—Metabolism—TYMS—rectum cancer	8.83e-05	0.0016	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—rectum cancer	8.65e-05	0.00156	CbGpPWpGaD
Carvedilol—KCNH2—Neuronal System—HRAS—rectum cancer	8.6e-05	0.00156	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—HRAS—rectum cancer	8.41e-05	0.00152	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—NRAS—rectum cancer	8.2e-05	0.00148	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HRAS—rectum cancer	8.07e-05	0.00146	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—NRAS—rectum cancer	8.05e-05	0.00146	CbGpPWpGaD
Carvedilol—HIF1A—Disease—KRAS—rectum cancer	7.77e-05	0.00141	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—rectum cancer	7.68e-05	0.00139	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	7.62e-05	0.00138	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	7.44e-05	0.00135	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—KRAS—rectum cancer	7.06e-05	0.00128	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—KRAS—rectum cancer	6.93e-05	0.00125	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—rectum cancer	6.61e-05	0.0012	CbGpPWpGaD
Carvedilol—HIF1A—Disease—HRAS—rectum cancer	6.61e-05	0.0012	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	6.33e-05	0.00114	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NRAS—rectum cancer	6.32e-05	0.00114	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—rectum cancer	6.16e-05	0.00111	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—HRAS—rectum cancer	6e-05	0.00109	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—HRAS—rectum cancer	5.89e-05	0.00107	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—rectum cancer	5.62e-05	0.00102	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—KRAS—rectum cancer	5.44e-05	0.000985	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—rectum cancer	4.84e-05	0.000875	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—NRAS—rectum cancer	4.74e-05	0.000858	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	4.67e-05	0.000845	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—NRAS—rectum cancer	4.63e-05	0.000838	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—HRAS—rectum cancer	4.63e-05	0.000837	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—NRAS—rectum cancer	4.43e-05	0.000802	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	4.15e-05	0.000751	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—TYMS—rectum cancer	4.14e-05	0.00075	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—TYMS—rectum cancer	4.14e-05	0.000748	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—KRAS—rectum cancer	4.08e-05	0.000739	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—KRAS—rectum cancer	3.98e-05	0.000721	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—KRAS—rectum cancer	3.81e-05	0.00069	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—rectum cancer	3.63e-05	0.000657	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NRAS—rectum cancer	3.6e-05	0.000651	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—HRAS—rectum cancer	3.47e-05	0.000628	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—rectum cancer	3.39e-05	0.000613	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—HRAS—rectum cancer	3.39e-05	0.000613	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—TYMS—rectum cancer	3.37e-05	0.000609	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—HRAS—rectum cancer	3.24e-05	0.000587	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—KRAS—rectum cancer	3.1e-05	0.000561	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—TYMS—rectum cancer	3.09e-05	0.000559	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—NRAS—rectum cancer	3.02e-05	0.000546	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—TYMS—rectum cancer	2.91e-05	0.000527	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—rectum cancer	2.75e-05	0.000498	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—NRAS—rectum cancer	2.75e-05	0.000497	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NRAS—rectum cancer	2.73e-05	0.000495	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NRAS—rectum cancer	2.73e-05	0.000494	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—NRAS—rectum cancer	2.72e-05	0.000493	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—NRAS—rectum cancer	2.69e-05	0.000486	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—rectum cancer	2.63e-05	0.000476	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—KRAS—rectum cancer	2.6e-05	0.00047	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—NRAS—rectum cancer	2.54e-05	0.00046	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—NRAS—rectum cancer	2.5e-05	0.000453	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—rectum cancer	2.36e-05	0.000428	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—rectum cancer	2.35e-05	0.000426	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—rectum cancer	2.35e-05	0.000425	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—rectum cancer	2.34e-05	0.000424	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—TYMS—rectum cancer	2.33e-05	0.000421	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—rectum cancer	2.31e-05	0.000419	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—NRAS—rectum cancer	2.22e-05	0.000402	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—rectum cancer	2.21e-05	0.000399	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—TYMS—rectum cancer	2.19e-05	0.000397	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—rectum cancer	2.19e-05	0.000396	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—TYMS—rectum cancer	2.17e-05	0.000393	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—rectum cancer	2.15e-05	0.00039	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—rectum cancer	2.09e-05	0.000378	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—rectum cancer	2.09e-05	0.000378	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—NRAS—rectum cancer	2.07e-05	0.000374	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—rectum cancer	2.01e-05	0.000364	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—rectum cancer	2e-05	0.000362	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—rectum cancer	2e-05	0.000361	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—rectum cancer	1.99e-05	0.00036	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—rectum cancer	1.97e-05	0.000356	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—rectum cancer	1.91e-05	0.000346	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—rectum cancer	1.86e-05	0.000337	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—TYMS—rectum cancer	1.86e-05	0.000336	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—rectum cancer	1.83e-05	0.000331	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—rectum cancer	1.78e-05	0.000322	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—rectum cancer	1.78e-05	0.000322	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—rectum cancer	1.63e-05	0.000294	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—rectum cancer	1.62e-05	0.000294	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—rectum cancer	1.61e-05	0.000291	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—rectum cancer	1.59e-05	0.000287	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—rectum cancer	1.53e-05	0.000277	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—rectum cancer	1.51e-05	0.000273	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—rectum cancer	1.5e-05	0.000272	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—rectum cancer	1.48e-05	0.000268	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—TYMS—rectum cancer	1.43e-05	0.000259	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—rectum cancer	1.4e-05	0.000253	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—rectum cancer	1.38e-05	0.00025	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—rectum cancer	1.37e-05	0.000247	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—rectum cancer	1.36e-05	0.000247	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—rectum cancer	1.31e-05	0.000238	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—rectum cancer	1.3e-05	0.000236	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—rectum cancer	1.29e-05	0.000234	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—rectum cancer	1.27e-05	0.00023	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—rectum cancer	1.24e-05	0.000225	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—rectum cancer	1.23e-05	0.000223	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—rectum cancer	1.22e-05	0.000221	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—rectum cancer	1.21e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—rectum cancer	1.19e-05	0.000215	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—rectum cancer	1.18e-05	0.000213	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—rectum cancer	1.16e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—rectum cancer	1.15e-05	0.000208	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—rectum cancer	1.13e-05	0.000205	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—rectum cancer	1.13e-05	0.000205	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—rectum cancer	1.1e-05	0.000199	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—rectum cancer	1.08e-05	0.000196	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—rectum cancer	1.05e-05	0.00019	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—rectum cancer	1e-05	0.000182	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—rectum cancer	9.61e-06	0.000174	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—rectum cancer	9.33e-06	0.000169	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—rectum cancer	8.93e-06	0.000162	CbGpPWpGaD
